BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 573 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $61,538,228 | +16.0% | 858,873 | +13.9% | 0.01% | +11.1% |
Q1 2024 | $53,066,572 | -6.3% | 753,894 | +2.7% | 0.01% | -10.0% |
Q4 2023 | $56,661,448 | +50.5% | 734,337 | +32.8% | 0.01% | +25.0% |
Q3 2023 | $37,640,067 | -29.7% | 552,961 | -15.7% | 0.01% | -27.3% |
Q2 2023 | $53,518,606 | +67.8% | 655,624 | +52.5% | 0.01% | +57.1% |
Q1 2023 | $31,886,057 | +63.8% | 429,789 | +83.0% | 0.01% | +40.0% |
Q4 2022 | $19,462,645 | +128383.3% | 234,829 | +340.3% | 0.01% | +25.0% |
Q3 2022 | $15,148 | -24.7% | 53,337 | -8.0% | 0.00% | -20.0% |
Q2 2022 | $20,105 | -99.9% | 58,003 | -16.3% | 0.01% | -16.7% |
Q1 2022 | $30,020,000 | -53.8% | 69,323 | -44.8% | 0.01% | -53.8% |
Q4 2021 | $64,940,000 | +2.6% | 125,528 | -3.9% | 0.01% | 0.0% |
Q3 2021 | $63,272,000 | -34.1% | 130,572 | -38.7% | 0.01% | -38.1% |
Q2 2021 | $95,965,000 | -2.2% | 213,133 | -17.0% | 0.02% | -16.0% |
Q1 2021 | $98,107,000 | +47.8% | 256,871 | +22.8% | 0.02% | +47.1% |
Q4 2020 | $66,398,000 | +20.0% | 209,096 | -6.4% | 0.02% | +6.2% |
Q3 2020 | $55,338,000 | -5.2% | 223,379 | +1.1% | 0.02% | -11.1% |
Q2 2020 | $58,357,000 | +31.1% | 220,990 | -5.9% | 0.02% | +12.5% |
Q1 2020 | $44,528,000 | -1.7% | 234,831 | +13.8% | 0.02% | +33.3% |
Q4 2019 | $45,281,000 | +19.4% | 206,280 | +6.5% | 0.01% | +9.1% |
Q3 2019 | $37,914,000 | +56.7% | 193,762 | +66.9% | 0.01% | +57.1% |
Q2 2019 | $24,200,000 | -6.2% | 116,075 | -10.7% | 0.01% | -12.5% |
Q1 2019 | $25,795,000 | -9.9% | 129,915 | -34.3% | 0.01% | -11.1% |
Q4 2018 | $28,625,000 | -30.5% | 197,801 | -2.0% | 0.01% | -18.2% |
Q3 2018 | $41,203,000 | +90.4% | 201,864 | +38.0% | 0.01% | +83.3% |
Q2 2018 | $21,639,000 | +7.7% | 146,262 | +9.9% | 0.01% | +20.0% |
Q1 2018 | $20,096,000 | -30.6% | 133,052 | -40.5% | 0.01% | -28.6% |
Q4 2017 | $28,948,000 | +20.8% | 223,451 | +12.7% | 0.01% | +16.7% |
Q3 2017 | $23,958,000 | -31.8% | 198,184 | -33.7% | 0.01% | -33.3% |
Q2 2017 | $35,107,000 | +33.2% | 298,783 | +15.2% | 0.01% | +28.6% |
Q1 2017 | $26,352,000 | +6.4% | 259,249 | +7.6% | 0.01% | 0.0% |
Q4 2016 | $24,768,000 | -22.8% | 240,860 | -17.8% | 0.01% | -30.0% |
Q3 2016 | $32,102,000 | -3.0% | 293,171 | -0.1% | 0.01% | -9.1% |
Q2 2016 | $33,093,000 | +11.3% | 293,463 | -6.7% | 0.01% | +10.0% |
Q1 2016 | $29,725,000 | +171.7% | 314,482 | +158.7% | 0.01% | +233.3% |
Q4 2015 | $10,940,000 | +46.2% | 121,552 | +50.1% | 0.00% | 0.0% |
Q3 2015 | $7,485,000 | -15.5% | 80,957 | -10.0% | 0.00% | 0.0% |
Q2 2015 | $8,857,000 | +8.1% | 89,945 | +10.1% | 0.00% | 0.0% |
Q1 2015 | $8,195,000 | -7.3% | 81,716 | -14.6% | 0.00% | 0.0% |
Q4 2014 | $8,838,000 | – | 95,656 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |